Diseases with loose connective tissue lesions due to immune and inflammatory responses are collectively known as rheumatoid connective tissue disorders, which include lupus erythematosus, dermatomyositis, systemic scleroderma, rheumatoid arthritis, desiccation, and symptomatic polyarteritis nodosa, among other diseases. Connective tissue disease can be found mucous edema, necrotizing vasculitis and fibrin-like degeneration filled with loose connective tissue. Clinical manifestations are arthritis, inflammatory myopathy, interstitial lung lesions, pulmonary hypertension, inflammatory vasculitis, plasma membrane inflammation, esophageal motility disorders, and Raynaud’s phenomenon. The treatment of connective tissue disease is based on different strategies for different categories. However, glucocorticoid drugs such as prednisone, non-steroidal anti-inflammatory drugs such as indomethacin and celecoxib, anti-rheumatic drugs such as methotrexate, cyclophosphamide and hydroxychloroquine, and biologics such as infliximab and tolizumab can be used. It is recommended that patients go to the rheumatology and immunology department of regular hospitals for treatment according to their own symptoms in time, so as to avoid delaying the disease and causing serious consequences.